Petrelintide_Dosage, benefits & legal status
Also known as ZP8396, petrilintide
An experimental weekly fullness-hormone shot for weight loss.
Common vial size is what vendors typically sell, not a recommendation. Enter your own vial in the calculator.
What is Petrelintide?
Plain language first. The technical label stays, but it never stands alone.Overview
What it's used for
An experimental weekly shot that copies a natural fullness hormone to reduce appetite, positioned as a gentler standalone option.
How does Petrelintide work?
What it does in the body, and where.Petrelintide is a long-acting amylin copy positioned as a standalone weight-loss drug rather than an add-on to a GLP-1.
- 01It works through amylin receptorsFullness signaled through the brainstem rather than the gut-hormone route.
- 02Positioned on tolerability rather than maximum lossThe pitch is fewer gut side effects than GLP-1 drugs, at some cost in weight lost. Whether that trade holds up is what the trials are testing.
- 03Still investigationalBoth Phase 2 trials have reported. The registrational Phase 3 program began in September 2026, with its primary endpoint at week 64. No approval anywhere.
What else is it used for?
Each use below carries its own evidence level. Approved means regulators have cleared it for that purpose. Investigational means it is in trials. Early research means it is being studied and is not established.
- Weight loss, positioned as a gentler standalone option than the GLP-1 drugsInvestigational
The published record
Papers and trials about Petrelintide
Searched: Petrelintide, ZP8396.
20 papers tagged human · 4 not reviews or lab · 2 clinical trial publications
12 registered trials · none with posted results
Furthest stage reached: Phase 3, under way
Counted from Europe PMC indexing, not read by a person; a human tag can land on reviews, commentary or lab papers; clinical trial publications is the narrower count.
At a glance
Four things to know about Petrelintide
Evidence
Investigational
Category
Weight loss and metabolic
Common vial
10 mg
Half-life
About 10 days
How much, and do you cycle it?
The range, and whether you take breaks.1.0 up to 9.0 mg per week (trial maintenance doses, not an approved dose), weekly. Not cycled in the trials Trial dose
Given continuously for the whole study period: ZUPREME-1, 42 weeks. The dose is stepped up at the start, which is a ramp rather than a cycle, and no trial in this class built in a planned break.
About 10 daysTrial protocol
Source: Braendholt Olsen, et al. Diabetes Obes Metab 2026, DOI 10.1111/dom.70753. ADA 2023 abstract 92-LB
You can compare this against the whole library to see where it sits.
How do I dose and price it?
Enter your vial and your dose. Pick a mix. We show the draw and the cost.The vial holds a fixed amount of drug. Adding more water does not make more drug, it just spreads it thinner, so you draw a bigger number on the syringe for the same dose.
Choose your mix
Measuring the water1 mL = one full 100-unit syringe.
We track Petrelintide at 1 vendor, and publishes its price.
1 listing, last read Oct 24, 2026. Shipping and card fees are not included.
How do you store it?
Before mixing, and after.Dry powder in the freezer or fridge. Once mixed, fridge, and use within about a month.
Unmixed lyophilized Petrelintide keeps for a long time cold. Once you add water the clock starts: most reconstituted vials hold up for roughly 28 to 30 days at fridge temperature. Keep it out of light, and do not freeze it after mixing.
What are the side effects and cautions?
Known cautions and warnings for this compound.Solubility, computed: 31% charged residues, 33% hydrophobic. Water usually sufficient.
A first-pass rule from peptide manufacturers' guidance. It does not account for disulfide bridges, salt form or how the powder was dried, and it predicts what should be easy rather than what will happen in your vial.
Who should avoid it
- Pregnancy or breastfeeding
- Any prescription medicine you take regularly, without checking for interactions first
- Anyone who needs established long-term safety or drug-interaction data; the completed Phase 2 trials do not establish either.
Stop and get help
- Spreading hives, swelling of the face or throat, or trouble breathing, which can happen with any injection and is a medical emergency
- Redness, heat, or pus at the injection site, which can signal infection
- Any severe or unexpected symptom
- Anything unusual; the Phase 2 safety reports cannot rule out rare or long-term harms.
Common effects
- Stomach side effects.
- Trial-only.
- Redness, soreness, or a small bump at the injection site
- The published Phase 2 trial recorded nausea in 20% of participants against 6% on placebo, vomiting in 3% against 6%, and discontinuation for any adverse event in 4% against 5%. Long-term safety is still unknown.
Where this page says nothing is established, that means nobody has studied it, not that a compound is safe.
Is Petrelintide approved?
And where the numbers on this page come from.No. Petrelintide is not approved anywhere and is currently in company-run clinical trials. There is no legal route to obtain it outside a trial.
- Approval statusInvestigational
- RouteUnder the skin (subcutaneous)
- Checked10 October 2026
- DoseFrom published clinical trials. Not approved by a regulator for this dose.
- Vial sizeFrom what vendors typically list; not a recommendation.
- SourcesNone traced yet.
What has happened recently
Early data suggests it is easier on the stomach than the GLP-1 drugs, but no trial has compared them. All three Phase 3 trials are placebo-controlled, so none will settle that comparison. It is not approved and long-term safety is unknown.
You can compare this against the whole library, or read how to check a seller.
What else is like Petrelintide?
Others in Amylin analogs, side by side.If you're weighing Petrelintide, it's worth reading Amycretin, ASC36, and AZD6234 in the same class.
An experimental weekly fullness-hormone shot for weight loss.
- Dose
- 1.0 up to 9.0 mg per week (trial maintenance doses, not an approved dose)
- How often
- Weekly
An experimental two-in-one weight-loss compound, as a pill or a shot.
- Dose
- 0.3 up to 60 mg per week
- How often
- Once weekly (injected)
An experimental amylin drug from Hong Kong-listed Ascletis, with rat and monkey data only and an undisclosed structure.
- Dose
- No human dose disclosed
- How often
- Monthly injection or daily tablet (intended)
An experimental weekly fullness-hormone shot from AstraZeneca, tuned to the amylin receptor.
- Dose
- Once weekly in trials; milligram dose levels have not been publicly disclosed
- How often
- Weekly
Guides for this compound
- How to Reconstitute a Peptide
Mix peptide powder with bacteriostatic water, step by step.
- How to Read an Insulin Syringe
Read the units, convert to millilitres, and draw the exact dose.
- mcg vs mg: The Peptide Dosing Mistake to Avoid
Your vial says mg and your protocol says mcg. Here is the conversion and how to check it.
- How to Read a Peptide COA
What the purity number does and does not tell you, and how to spot an edited report.
- How to Vet a Peptide Vendor
Independent COAs, HPLC purity, and the red flags that mean walk away.
Sources
No primary source has been traced for this compound yet. Treat everything on this page as unverified until one is. How we grade evidence
Beyond these, 21 records are indexed. Browse the records
Read what ZUPREME-2 reported, and the week it was measured; neither completed trial compared petrelintide with semaglutide.